CN Patent

CN118994033B — 一种sdnx-5613的合成方法及其中间体化合物

Assigned to Hitgen Inc · Expires 2025-09-16 · 1y expired

What this patent protects

本发明公开一种menin抑制剂SNDX‑5613(Revumenib)的合成方法及其中间体化合物。本发明的合成方法产率高，成本低，避免使用三氯氧磷，提高安全性。

USPTO Abstract

本发明公开一种menin抑制剂SNDX‑5613(Revumenib)的合成方法及其中间体化合物。本发明的合成方法产率高，成本低，避免使用三氯氧磷，提高安全性。

Drugs covered by this patent

Patent Metadata

Patent number
CN118994033B
Jurisdiction
CN
Classification
—
Expires
2025-09-16
Drug substance claim
No
Drug product claim
No
Assignee
Hitgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.